Detalles de la búsqueda
1.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Blood
; 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635762
2.
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Br J Haematol
; 204(1): 171-176, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37710381
3.
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Br J Haematol
; 204(4): 1243-1248, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38083865
4.
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Haematologica
; 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38546692
5.
Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Haematologica
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38813716
6.
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Haematologica
; 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38299584
7.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Am J Hematol
; 99(4): 606-614, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342997
8.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Am J Hematol
; 99(2): 193-202, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38071734
9.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Am J Hematol
; 99(2): E63-E66, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100217
10.
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
Cancer
; 129(6): 934-945, 2023 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36545710
11.
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Br J Haematol
; 202(2): 279-283, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37144345
12.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Haematologica
; 108(11): 3033-3043, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37199125
13.
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Haematologica
; 108(7): 1900-1908, 2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779595
14.
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants.
Am J Hematol
; 98(12): E357-E359, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37665761
15.
Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.
Future Oncol
; 19(27): 1877-1889, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750305
16.
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Cancer
; 127(7): 1039-1048, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33259056
17.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966625
18.
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Eur J Haematol
; 107(3): 301-310, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33973276
19.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Am J Hematol
; 96(11): 1374-1384, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324220
20.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Blood
; 141(9): 1087-1091, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36574363